VANCOUVER, BC, Dec. 17, 2021 /CNW/ - NeutriSci International Inc. ("NeutriSci" or the "Company") (TSX-V: NU) (OTCQB: NRXCF) (FSE: 1N9), announces that as a result of a review by the British Columbia Securities Commission it has refiled its management discussion & analysis for the six- and nine-month periods ended June 30, 2021 and September 30, 2021 (collectively, the "MD&A"). The refiled MD&A includes additional disclosure regarding a one-time financial loss incurred by the Company, and which was already reflected in the accompanying interim financial statements for these periods. No changes to the interim financial statements were made in connection with the refiling of the MD&A.
Copies of the refiled MD&A are available for review under the profile for the Company on SEDAR (www.sedar.com).
About NeutriSci International Inc.
NeutriSci specializes in the innovation, production, and formulation of nutraceutical products. Established in 2009, NeutriSci's is building sustainable sales models with Convenience, Chain Drug, and Mass Market and Supermarket retailers for its products offering co-branding as well as private label opportunities and contract manufacturing services. For more information, please visit: www.neutrisci.com.
On Behalf of the Board of Directors of
NEUTRISCI INTERNATIONAL INC.
Glen Rehman
CEO
Tel: (403) 264-6320
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.
This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward-looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.
SOURCE NeutriSci International Inc.
For investor inquiries, please contact [email protected]
Share this article